Leerink Partners has upgraded Bristol-Myers Squibb & Co (NYSE:BMY), stating that the company enters a catalyst-rich period in 2025-2027 beyond Cobenfy (a schizophrenia drug) and milvexian (anticoagulant).
The analyst expects upward pressure on Cobenfy (KarXT) and milvexian consensus expectations to drive stock outperformance from current levels.
Also Read: Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Leerink has upgraded from Market Perform to Outperform, with a price target of $73, up from the previous $55, and adds that Bristol-Myers stock trades a substantial discount to the Diversified Biopharmaceutical median due to constrained EPS growth through 2029.
But the U.S. pharma giant’s exposure to loss of exclusivity (LOE) …
Full story available on Benzinga.com